Capital Research Global Investors
MYGN icon

Capital Research Global Investors’s Myriad Genetics MYGN Stock Holding History

Capital Research Global Investors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,244,300
Closed -$20.7M – 435
2016
Q4 		$20.7M Sell
1,244,300
-3,179,058
-72% -$57.5M 0.01% 385
2016
Q3 		$91M Sell
4,423,358
-3,058,777
-41% -$77.6M 0.03% 280
2016
Q2 		$229M Sell
7,482,135
-1,138,704
-13% -$39.6M 0.08% 209
2016
Q1 		$323M Sell
8,620,839
-252,193
-3% -$9.5M 0.11% 173
2015
Q4 		$383M Sell
8,873,032
-67,670
-0.8% -$2.86M 0.13% 157
2015
Q3 		$335M Hold
8,940,702
– – 0.12% 169
2015
Q2 		$304M Hold
8,940,702
– – 0.1% 204
2015
Q1 		$317M Hold
8,940,702
– – 0.11% 193
2014
Q4 		$305M Buy
8,940,702
+7,268
+0.1% +$258K 0.1% 199
2014
Q3 		$345M Buy
8,933,434
+215,825
+2% +$8.05M 0.12% 175
2014
Q2 		$339M Buy
8,717,609
+288,251
+3% +$10.7M 0.12% 170
2014
Q1 		$288M Buy
8,429,358
+804,473
+11% +$24.9M 0.1% 186
2013
Q4 		$160M Buy
7,624,885
+1,888,185
+33% +$47.8M 0.06% 235
2013
Q3 		$135M Buy
5,736,700
+3,035,800
+112% +$86.2M 0.05% 246
2013
Q2 		$72.6M Buy
+2,700,900
New +$78.3M 0.03% 289

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital Research Global Investors's MYGN Position: Q1 2017 in Review

Capital Research Global Investors sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 1,244,300 shares — an estimated $20.7M sold.

Capital Research Global Investors first reported a position in MYGN in Q2 2013 and held it in 15 quarters. The position peaked at $383M in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

  • Capital Research Global Investors reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
  • Capital Research Global Investors sold 1,244,300 Myriad Genetics shares in Q1 2017, an estimated $20.7M.
  • Capital Research Global Investors first reported a position in Myriad Genetics in Q2 2013 and held it in 15 quarters.
  • Capital Research Global Investors's Myriad Genetics position peaked at $383M in Q4 2015.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Capital Research Global Investors's 13F filing for Q1 2017, filed 15 May 2017.